Trulieve Cannabis Corp
CNSX:TRUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (8.7), the stock would be worth CA$12.55 (8% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.4 | CA$13.69 |
0%
|
| 3-Year Average | 8.7 | CA$12.55 |
-8%
|
| 5-Year Average | 4.8 | CA$7.02 |
-49%
|
| Industry Average | 19.8 | CA$28.78 |
+110%
|
| Country Average | 23.2 | CA$33.67 |
+146%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
T
|
Trulieve Cannabis Corp
CNSX:TRUL
|
2.6B CAD | 9.4 | -15.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 34.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 19 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 24.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 42.2 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Trulieve Cannabis Corp
Glance View
Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. The company is headquartered in Quincy, Florida and currently employs 9,000 full-time employees. The company went IPO on 2018-09-25. The firm is a multi-state operator in the United States operating in states, with market positions in Arizona, Florida, and Pennsylvania. The company is providing products across its brand portfolio and delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. The company operates in regulated markets that require knowledge in cultivation, manufacturing, retail and logistics. The firm utilizes critical ethanol extraction to obtain the cannabis oil used in its products. The company also utilizes carbon dioxide (CO2) extraction for terpene extraction as well as a line of CO2 vaporizer cartridges. The firm has developed a suite of products with stock keeping units (SKUs), including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays.
